Savara Past Earnings Performance
Past criteria checks 0/6
Savara has been growing earnings at an average annual rate of 9.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 16.3% per year.
Key information
9.4%
Earnings growth rate
43.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -16.3% |
| Return on equity | -39.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Savara makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -55 | 16 | 0 |
| 30 Sep 23 | 0 | -49 | 14 | 0 |
| 30 Jun 23 | 0 | -43 | 12 | 0 |
| 31 Mar 23 | 0 | -40 | 12 | 0 |
| 31 Dec 22 | 0 | -38 | 11 | 0 |
| 30 Sep 22 | 0 | -39 | 11 | 0 |
| 30 Jun 22 | 0 | -39 | 12 | 0 |
| 31 Mar 22 | 0 | -41 | 12 | 0 |
| 31 Dec 21 | 0 | -43 | 12 | 0 |
| 30 Sep 21 | 0 | -45 | 12 | 0 |
| 30 Jun 21 | 0 | -46 | 12 | 0 |
| 31 Mar 21 | 0 | -44 | 12 | 0 |
| 31 Dec 20 | 0 | -50 | 12 | 0 |
| 30 Sep 20 | 0 | -68 | 12 | -30 |
| 30 Jun 20 | 0 | -69 | 12 | -20 |
| 31 Mar 20 | 0 | -81 | 13 | -10 |
| 31 Dec 19 | 0 | -78 | 13 | 0 |
| 30 Sep 19 | 0 | -57 | 13 | 40 |
| 30 Jun 19 | 0 | -57 | 13 | 40 |
| 31 Mar 19 | 0 | -47 | 11 | 39 |
| 31 Dec 18 | 0 | -62 | 10 | 37 |
| 30 Sep 18 | 0 | -58 | 8 | 34 |
| 30 Jun 18 | 0 | -52 | 9 | 29 |
| 31 Mar 18 | 0 | -53 | 7 | 24 |
| 31 Dec 17 | 0 | -31 | 7 | 19 |
| 30 Sep 17 | 0 | -28 | 7 | 16 |
| 30 Jun 17 | 0 | -25 | 4 | 13 |
| 31 Mar 17 | 0 | -14 | 4 | 10 |
| 31 Dec 16 | 0 | -11 | 3 | 8 |
| 31 Dec 15 | 0 | -9 | 2 | 4 |
| 31 Dec 14 | 2 | -6 | 2 | 5 |
Quality Earnings: YB4P is currently unprofitable.
Growing Profit Margin: YB4P is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: YB4P is unprofitable, but has reduced losses over the past 5 years at a rate of 9.4% per year.
Accelerating Growth: Unable to compare YB4P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YB4P is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: YB4P has a negative Return on Equity (-38.97%), as it is currently unprofitable.